liposomal Magnesium Carbonate 80% — High Bioavailability Magnesium Supplement

Product Overview

Liposomal Magnesium Carbonate 80% is a premium-grade dietary supplement ingredient delivering magnesium carbonate in an advanced liposomal delivery system. Magnesium carbonate (CAS 546-93-0 for anhydrous; CAS 39409-82-0 for basic form), also known as magnesite, is an inorganic salt composed of magnesium cations (Mg²⁺) and carbonate anions (CO₃²⁻). It is chemically characterized by the molecular formula MgCO₃ and a molecular weight of 84.31 g/mol. Magnesium carbonate occurs naturally as the mineral magnesite and exists in several hydrated forms including barringtonite (MgCO₃·2H₂O), lansfordite (MgCO₃·5H₂O), and nesquehonite (MgCO₃·3H₂O). The compound is available as a white, odorless crystalline powder that is practically insoluble in water (0.01 g/100 mL at 20°C) but dissolves readily in dilute acids.

Magnesium is the fourth most abundant cation in the human body and serves as an essential cofactor for more than 300 enzymatic reactions, including all enzymatic processes involving ATP. It plays a critical role in neurochemical transmission and muscular excitability, and is essential for maintaining normal bone density, cardiac rhythmicity, pulmonary function, and blood glucose regulation. Magnesium carbonate is widely utilized in pharmaceutical and nutraceutical formulations due to its high elemental magnesium content and excellent gastrointestinal tolerance profile.

Why Liposomal Technology?

Conventional magnesium carbonate presents significant formulation challenges. The compound has poor aqueous solubility and is classified as an inorganic magnesium salt, which generally exhibits lower bioavailability compared to organic magnesium forms such as gluconate, citrate, and amino acid chelates. Approximately 4% to 23% of magnesium from inorganic salts such as magnesium oxide is absorbed, compared to 50% to 67% for top organic chelates.

Liposomal encapsulation provides four critical advantages:

1. Superior Bioavailability and Sustained Plasma Levels — A randomized, controlled, two-group human clinical trial in 20 metabolically healthy volunteers compared the bioavailability of 400 mg magnesium in liquid liposomal form versus non-liposomal tablet form. The liquid liposomal magnesium supplement achieved up to 5.18 times higher bioavailability than the non-liposomal tablet form and maintained elevated plasma levels throughout the entire study period, demonstrating sustained high concentrations during daily supplementation. This represents a significant enhancement over conventional magnesium carbonate, which relies on gastric acid for dissolution and absorption.

2. Enhanced Cellular Uptake — liposomes fuse directly with intestinal cell membranes, facilitating efficient cellular delivery via lipid-mediated pathways. The liposomal delivery system bypasses the saturable nature of carrier-mediated magnesium transport, providing an alternative route of cellular entry. The liposomal matrix may help uptake in the small intestine by providing a protective structure that remains stable until reaching the optimal absorption site.

3. Gastrointestinal Protection — The phospholipid bilayer shields the magnesium-carbonate complex from premature interaction with gastric contents, protecting the mineral from the acidic pH of the stomach. This special structure avoids any reaction with the intestinal wall and allows direct absorption into the bloodstream. Liposomal encapsulation minimizes the laxative effect commonly associated with conventional magnesium salts by reducing direct mucosal contact.

4. Dual-Ion Delivery — Magnesium carbonate provides both magnesium and carbonate ions. The carbonate component contributes to the antacid activity of the compound, neutralizing excess stomach acid while the liposomal delivery system ensures efficient magnesium absorption.

Product Specifications

Key Features

• High Purity — Standardized to ≥80% magnesium carbonate, with MgO equivalent of 40.0%–43.5% (USP) and elemental magnesium content of 25.0%–28.8%.

• Liposomal Enhancement — Phospholipid bilayer encapsulation achieves up to 5.18 times higher bioavailability compared to non-liposomal magnesium in tablet form in human clinical study, with sustained elevated plasma levels maintained throughout the study period.

• Superior Gastrointestinal Tolerance — Magnesium carbonate exhibits a relatively good gastrointestinal tolerance profile and has been proposed as a valid alternative phosphate binder to calcium acetate, allowing hemodialysis patients to reduce their calcium load.

• Phosphate Binding — Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients and prevents vascular calcification in these patients. It effectively controls serum phosphate levels and reduces aortic calcification.

• Muscle and Nervous System Support — Magnesium prevents or controls convulsions by blocking neuromuscular transmission and decreasing the amount of acetylcholine liberated at the end-plate by the motor nerve impulse.

• Mitral Valve Prolapse Symptom Relief — Many patients with heavily symptomatic mitral valve prolapse syndrome have low serum magnesium, and supplementation by means of magnesium carbonate leads to improvement in most symptoms.

• Antacid Activity — Magnesium carbonate is used for relief of gastrointestinal symptoms of dyspepsia, heartburn, gastroesophageal reflux disease, and constipation, acting as an antacid and laxative.

• Water-Dispersible — Liposomal powder offers excellent dispersibility in water compared to standard magnesium carbonate; suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Clinical studies and commercial products commonly recommend 200–400 mg of elemental magnesium per day from magnesium carbonate. A representative commercial effervescent tablet contains 320 mg of magnesium from magnesium carbonate hydrate, with a suggested intake of one tablet daily dissolved in 200 mL of water. Another commercial product provides 172 mg of elemental magnesium per tablet, with the same daily dosage recommendation. For phosphate binding in chronic hemodialysis patients, a clinical study used 250 mg magnesium carbonate three times daily with meals, with the dose of each binder titrated to achieve the K/DOQI phosphate target of <5.5 mg/dL. The Recommended Dietary Allowance (RDA) for elemental magnesium is 310–320 mg/day for adult females and 400–420 mg/day for adult males. The Tolerable Upper Intake Level (UL) for supplemental magnesium is 350 mg/day for adults. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.